CARDIOVASCULAR EFFECTS OF AN ARGINASE II SELECTIVE INHIBITOR

For the first time in vitro experiments there were studied the inhibitory activity and safety of potential molecules arginase II selective inhibitors from the group of norleucine derivatives. Also first the substance under the code ZB49-0010C from the group of norleucine derivatives showed the great...

Full description

Bibliographic Details
Main Authors: Vladimir Yakushev, Mikhail Pokrovskii
Format: Article
Language:English
Published: Belgorod National Research University 2016-09-01
Series:Research Results in Pharmacology
Subjects:
Online Access:https://rrpharmacology.pensoft.net/article/31082/download/pdf/
_version_ 1827613078489923584
author Vladimir Yakushev
Mikhail Pokrovskii
author_facet Vladimir Yakushev
Mikhail Pokrovskii
author_sort Vladimir Yakushev
collection DOAJ
description For the first time in vitro experiments there were studied the inhibitory activity and safety of potential molecules arginase II selective inhibitors from the group of norleucine derivatives. Also first the substance under the code ZB49-0010C from the group of norleucine derivatives showed the greatest selectivity and inhibitory activity against arginase II in experiments in vitro. However, this substance in vivo exerts dose-dependent hypotensive action and cardioprotective and endothelial protective effects on the L-NAME induced and homocysteine-induced endothelial dysfunction (ED), which are most pronounced at a dose of 10 mg/kg in intragastric administration. Endothelial protective effect consists of in preventing the increase of coefficient of endothelial dysfunction (CED) and the decrease in the concentration of stable metabolites of nitric oxide in the blood plasma. Cardioprotective effect consists of in preventing the increase of the level of left ventricular pressure during the test for adrenoreactivity and reducing of the cardiac reserve during the overload resistance test, and also in preventing the development of the left ventricular hypertrophy. As part of the study there was investigated the dose-dependent anti-ischemic effect of the arginase II selective inhibitor, substance ZB49-0010C on the chronic limb ischemia in rats, which most pronounced at a dose of 10 mg/kg and consists of in preventing the fall in microcirculatory level on the 29th day of the experiment in the ischemic limb and a protective effect based on the morphological examination of the muscle tissue.
first_indexed 2024-03-09T08:34:41Z
format Article
id doaj.art-1f4c9e0a72394401b3ac7fdf823e96b6
institution Directory Open Access Journal
issn 2658-381X
language English
last_indexed 2024-03-09T08:34:41Z
publishDate 2016-09-01
publisher Belgorod National Research University
record_format Article
series Research Results in Pharmacology
spelling doaj.art-1f4c9e0a72394401b3ac7fdf823e96b62023-12-02T18:41:11ZengBelgorod National Research UniversityResearch Results in Pharmacology2658-381X2016-09-0123284510.18413/2500-235X-2016-2-3-28-4531082CARDIOVASCULAR EFFECTS OF AN ARGINASE II SELECTIVE INHIBITORVladimir YakushevMikhail PokrovskiiFor the first time in vitro experiments there were studied the inhibitory activity and safety of potential molecules arginase II selective inhibitors from the group of norleucine derivatives. Also first the substance under the code ZB49-0010C from the group of norleucine derivatives showed the greatest selectivity and inhibitory activity against arginase II in experiments in vitro. However, this substance in vivo exerts dose-dependent hypotensive action and cardioprotective and endothelial protective effects on the L-NAME induced and homocysteine-induced endothelial dysfunction (ED), which are most pronounced at a dose of 10 mg/kg in intragastric administration. Endothelial protective effect consists of in preventing the increase of coefficient of endothelial dysfunction (CED) and the decrease in the concentration of stable metabolites of nitric oxide in the blood plasma. Cardioprotective effect consists of in preventing the increase of the level of left ventricular pressure during the test for adrenoreactivity and reducing of the cardiac reserve during the overload resistance test, and also in preventing the development of the left ventricular hypertrophy. As part of the study there was investigated the dose-dependent anti-ischemic effect of the arginase II selective inhibitor, substance ZB49-0010C on the chronic limb ischemia in rats, which most pronounced at a dose of 10 mg/kg and consists of in preventing the fall in microcirculatory level on the 29th day of the experiment in the ischemic limb and a protective effect based on the morphological examination of the muscle tissue.https://rrpharmacology.pensoft.net/article/31082/download/pdf/arginase II selective inhibitorsZB49-0010CL-NA
spellingShingle Vladimir Yakushev
Mikhail Pokrovskii
CARDIOVASCULAR EFFECTS OF AN ARGINASE II SELECTIVE INHIBITOR
Research Results in Pharmacology
arginase II selective inhibitors
ZB49-0010C
L-NA
title CARDIOVASCULAR EFFECTS OF AN ARGINASE II SELECTIVE INHIBITOR
title_full CARDIOVASCULAR EFFECTS OF AN ARGINASE II SELECTIVE INHIBITOR
title_fullStr CARDIOVASCULAR EFFECTS OF AN ARGINASE II SELECTIVE INHIBITOR
title_full_unstemmed CARDIOVASCULAR EFFECTS OF AN ARGINASE II SELECTIVE INHIBITOR
title_short CARDIOVASCULAR EFFECTS OF AN ARGINASE II SELECTIVE INHIBITOR
title_sort cardiovascular effects of an arginase ii selective inhibitor
topic arginase II selective inhibitors
ZB49-0010C
L-NA
url https://rrpharmacology.pensoft.net/article/31082/download/pdf/
work_keys_str_mv AT vladimiryakushev cardiovasculareffectsofanarginaseiiselectiveinhibitor
AT mikhailpokrovskii cardiovasculareffectsofanarginaseiiselectiveinhibitor